The benefits of electronic Clinical Outcome Assessment (eCOA) have been widely published for decades. Yet, nearly half of all studies that collect patient outcome data do so using primarily paper solutions.
Researchers cite different reasons for clinging to paper COA, including the misunderstanding that eCOA is only suitable for large, global companies, but hundreds of small pharma, biotechs and CROs are benefitting from using eCOA in their clinical trials every day.
This article demystifies some of the common myths about using eCOA in clinical trials, and presents the core advantages to all clinical trial sponsors & CROs, regardless of their size.
Read the full article below, or download it here.ERT_Debunking_eCOA_in_Myths___BioPharma_Dive_April_2018